AdaptHealth Corp. distributes home medical equipment, medical supplies, and related home services in the United States through its subsidiaries. It operates in four segments: Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home. The company provides sleep therapy equipment such as CPAP and BiLevel devices, oxygen and home mechanical ventilation, and diabetes devices including continuous glucose monitors and insulin pumps. It also offers a range of other home medical equipment and supplies, serving beneficiaries of Medicare, Medicaid, and commercial insurance payors. Founded in 2012, AdaptHealth Corp. is headquartered in Conshohocken, Pennsylvania.
Cardinal Health Expects Growth to Normalize in Fiscal 2027 After Strong Fiscal 2026
Cardinal Health expects growth to normalize in fiscal 2027 after fiscal 2026 delivered double-digit earnings growth in all five operating segments, CEO Jason Hollar said at a Baird event. Hollar said the prior year's outperformance was driven by strong healthcare utilization, specialty growth, new customer wins, acquisitions and operational execution, and that unusually strong specialty growth and customer onboarding will be less pronounced in fiscal 2027. Cardinal's specialty business grew 25% in fiscal 2026, and the company is expanding its specialty and at-home strategy through three managed-services organization platforms focused on oncology, urology and gastroenterology, plus bolt-on acquisitions, including four completed in the most recent quarter. The Strive Medical acquisition has closed, while the purchase of AdaptHealth's diabetes business is expected to close in the second half of fiscal 2027, expanding Cardinal's continuous glucose monitoring presence; Hollar noted only 35% of people eligible for a CGM through insurance coverage actually have one. Cardinal plans to add three more automated distribution centers for small-parcel shipping of higher-value at-home products, and Hollar said cash flow was strong in fiscal 2026, putting the company about 90% of the way toward its previously announced $10 billion objective.
CAH · Capital · Positive Cardinal Health reported double-digit earnings growth in all five segments in fiscal 2026 and is about 90% toward its $10 billion cash flow objective, though it expects growth to normalize in fiscal 2027.
AHCO · Capital · Neutral Cardinal Health's purchase of AdaptHealth's diabetes business is expected to close in the second half of fiscal 2027, a divestiture mentioned only as context.
AdaptHealth Names Harriss Currie as Chief Financial Officer
AdaptHealth Corp. announced that its Board of Directors has named Harriss T. Currie as Chief Financial Officer, effective September 9, 2026. Currie will take over from Jason Clemens, who will assist with the transition through October 1, 2026. Currie previously served as CFO of Luminex Corp for over 15 years until its sale to DiaSorin in 2021, and held CFO roles at Health Track Rx and Impulse Dynamics, as well as President of the Regenerative Medicine division of 3D Systems. CEO Suzanne Foster expressed confidence in Currie's contributions, while Currie cited the company's strong leadership and strategic contracts as reasons for joining.
McKesson reported second-quarter revenues of $105.4 billion, up 7.7% year over year and 1.2% above analyst expectations, while its stock remained flat at $868.87. Among the 39 healthcare providers and services stocks tracked, aggregate revenues beat consensus by 1.7% and next-quarter guidance came in 1.6% above estimates, yet the group's average share price fell 1.2% since earnings. CVS Health posted the best quarter with revenues of $106.1 billion, up 7.3% and 6.7% above expectations, but its stock dropped 9.1% to $94.90. AdaptHealth was the weakest performer, missing revenue estimates by 12.6% with revenues of $740.3 million and issuing significantly lower full-year revenue and EBITDA guidance, sending its stock down 46.2% to $5.83. Elevance Health reported flat revenues of $49.83 billion, beating estimates by 2.5%, but lost 469,000 customers and saw its stock fall 7.4% to $395.18, while Quest Diagnostics grew revenues 10.2% to $3.04 billion and its stock rose 12.6% to $236.32.
AdaptHealth Sells Diabetes Unit to Cardinal Health to Focus on Sleep and Respiratory Growth
AdaptHealth is selling its roughly $600 million diabetes business to Cardinal Health and exiting certain e-commerce and drop-ship operations to simplify the company and focus on sleep, respiratory and home medical equipment. CEO Suzanne Foster said the diabetes segment did not offer expected cross-selling opportunities and would have required further investment in pharmacy capabilities and distribution infrastructure. The transaction will leave about $60 million of overhead costs with continuing operations, with roughly half expected to be removed in the first year after closing. The company reported 16% second-quarter revenue growth, but its new West Coast capitated contract covering 13 million members is facing higher-than-expected service costs due to utilization and hospital-ordering issues. Management sees strong growth potential in sleep care through higher referrals, home testing and digital tools, and capital priorities include organic growth, reducing leverage to 2.5 times and pursuing targeted sleep and respiratory acquisitions.
AdaptHealth Stock Plummets 47% After Disappointing Q2 Results and Guidance Cut
AdaptHealth stock fell 47% this week after the company reported second-quarter results that missed expectations and slashed its full-year guidance. The company posted a loss of $1.07 per share, far below the $0.15 profit analysts had forecast, while revenue of $740.3 million came in about $106.5 million below estimates. AdaptHealth now expects full-year sales between $2.85 billion and $2.89 billion, down from its prior range of $3.45 billion to $3.52 billion, largely due to discontinuing its Diabetes Health business. Adjusted EBITDA guidance was cut to $490 million to $520 million from $680 million to $730 million, and free cash flow is now seen at $80 million to $120 million, down from $175 million to $225 million.
Holzer & Holzer Investigates AdaptHealth Over Revised Guidance and Cash Flow Decline
Holzer & Holzer, LLC announced an investigation into whether AdaptHealth Corp. complied with federal securities laws. On August 4, 2026, AdaptHealth revised its financial guidance and reported second quarter results, disclosing that cash flow from operations fell to $239.0 million year-to-date 2026 from $257.5 million in the comparable 2025 period, while free cash flow turned negative to negative $48.4 million from $73.3 million. The company attributed the decline partly to its West Coast capitated partnership reaching full scale and the complexity of the transition impacting margins. Following the news, AdaptHealth's stock price dropped. The law firm encourages investors who purchased AdaptHealth stock and suffered a loss to contact Corey Holzer or Joshua Karr to discuss their legal rights.
AdaptHealth Corp. to report Q2 2026 earnings on August 4
AdaptHealth Corp. is scheduled to announce its second-quarter 2026 earnings results on Tuesday, August 4th, before the market opens. The consensus earnings per share estimate is $0.17, representing a 70.0% increase year-over-year, while the consensus revenue estimate is $846.77 million, up 5.8% from the same period last year. Over the last three months, EPS estimates have seen zero upward revisions and five downward revisions, and revenue estimates have seen six upward revisions and one downward revision.
Cardinal Health Stock Screens as Overvalued After Home Care Deal Push
Cardinal Health stock appears overvalued on earnings following its push into home-based care through planned acquisitions of Strive Medical and AdaptHealth's diabetes business. The stock trades at about 35.0 times earnings, above the healthcare industry average of roughly 26.9 times and a peer group average of about 28.1 times, and above a modeled fair P/E ratio near 29.2 times. While the home care deals may support growth expectations, integration and regulatory risks could weigh on value, and the stock passes only two of six broader valuation checks. The premium suggests investors are already pricing in optimism around the acquisitions, leaving new buyers reliant on strong execution rather than valuation support.
CAH · Capital · Negative Cardinal Health stock is deemed overvalued on earnings, trading at a premium above industry and peer averages, with only two of six valuation checks passing.
AHCO · Capital · Neutral AdaptHealth's diabetes business is being acquired by Cardinal Health, but the article focuses on Cardinal's valuation, not AdaptHealth's prospects.
Strive Medical · Capital · Neutral Strive Medical is being acquired by Cardinal Health, but the article does not discuss Strive's own valuation or performance.
Cardinal Health acquires Strive Medical and AdaptHealth diabetes unit for $360 million
Cardinal Health has acquired urology-focused medical supplier Strive Medical and the diabetes business of AdaptHealth in a pair of deals totaling $360 million, advancing its at-home solutions business. The diabetes unit purchase follows Cardinal's buyout of Advanced Diabetes Supply in April 2025, while the Strive Medical deal builds on recent urology acquisitions including the $1.9 billion Solaris Health transaction in August 2025. CEO Jason Hollar said the transactions expand the company's depth across diabetes management and urology, strengthening its leadership in home care. The at-home solutions business has already migrated all Advanced Diabetes Supply volume onto its distribution network, onboarded nearly 500,000 new customers, and launched a digital referral pathway program.
AdaptHealth sells diabetes unit to Cardinal Health for $235 million
AdaptHealth is divesting its Diabetes Health business to Cardinal Health in a $235 million cash deal. The unit provides continuous glucose monitors, insulin pumps, and related services for diabetes treatment. AdaptHealth says the sale will allow it to redeploy capital toward its core sleep and respiratory care segments, strengthen its balance sheet, and pursue growth opportunities. The transaction is subject to regulatory review and other closing conditions, with a financial update expected during AdaptHealth's second quarter 2026 earnings call on August 4. Deutsche Bank Securities is advising AdaptHealth, while J.P. Morgan Securities is advising Cardinal Health.
StockStory highlights iRhythm as a healthcare stock to watch while flagging AdaptHealth and Collegium Pharmaceutical as sells
StockStory named iRhythm Technologies as a healthcare stock to watch, citing its 23.9% annual revenue growth over two years and a move to positive free cash flow, while recommending investors avoid AdaptHealth and Collegium Pharmaceutical. AdaptHealth saw flat sales and a 12.4% annual decline in earnings per share over five years, with a 0.3% return on capital. Collegium Pharmaceutical's adjusted operating margin fell 6.4 percentage points as costs outpaced revenue, and its returns on capital stagnated. iRhythm trades at 351.1 times forward earnings, AdaptHealth at 11 times, and Collegium at 4.5 times.
AdaptHealth discloses June cyberattack resulting in patient data exposure
AdaptHealth has disclosed a June cyberattack that exposed patient data, including password files and protected health information. The home-based medical device provider said a threat actor contacted the company on June 15 claiming to have obtained data from its systems. The breach occurred through a social engineering attack that compromised a user session of a third-party contractor, granting access to cloud-based applications. AdaptHealth stated that no Social Security numbers, financial account details, or payment card information were exposed, as such data was not stored in the affected systems. The company has contained the incident and is continuing to investigate the full scope of the exfiltrated data.
BrightSpring Health Services Tops Q1 Senior Health, Home Health & Hospice Earnings
BrightSpring Health Services earned top marks among seven senior health, home health and hospice stocks tracked in the first quarter. The company reported revenues of $3.61 billion, up 25.6% year on year and beating analysts' expectations by 6.3%, while also exceeding EPS estimates and raising full-year EBITDA guidance. Chemed posted revenues of $657.5 million, a 1.6% increase that outperformed expectations by 1.2% and beat EPS estimates. Option Care Health was the weakest performer, with revenues of $1.35 billion missing estimates by 3.3% and full-year revenue guidance falling short. AdaptHealth reported $819.8 million in revenue, a 5.4% rise that beat estimates by 2.9%, though it missed EPS estimates significantly. Brookdale Senior Living saw revenues decline 6% to $764.9 million, missing estimates by 0.8% but beating EPS expectations. As a group, the seven companies' revenues beat consensus estimates by 0.9%, and their share prices have risen 7.6% on average since reporting.
United States